COMMUNIQUÉS West-GlobeNewswire

Naturally Splendid Expands Production Capability and Increases R&D with Newly Branded Bar Maker Division -- CFN Media
30/07/2018
SEATTLE, July 30, 2018 (GLOBE NEWSWIRE) -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, today announced publication of an article [...]
Sedor Pharmaceuticals NDA for CE-Fosphenytoin for Status Epilepticus Receives PDUFA Date
30/07/2018
Potential significant advance for life threatening condition PAOLI, Pa., July 30, 2018 (GLOBE NEWSWIRE) -- Sedor Pharmaceuticals, LLC (Sedor) announced that the US FDA accepted its 505(b)2 NDA (210864) for Sedor’s lead [...]
Teligent, Inc. Announces FDA Approval of Hydrocortisone Lotion USP, 2.5%
30/07/2018
BUENA, N.J., July 30, 2018 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced it has received approval of the Company’s abbreviated new drug [...]
AIT Therapeutics Announces Start of Manufacturing of Ventilator Compatible NO Generator and Delivery System
30/07/2018
FDA 510(k) submission expected in the first quarter of calendar 2019 Sparton's Watertown facility to provide manufacturing services GARDEN CITY, N.Y. and REHOVOT, Israel, July 30, 2018 (GLOBE NEWSWIRE) -- AIT [...]
Iovance Biotherapeutics to Host Second Quarter 2018 Financial Results Conference Call and Webcast on Monday, August 6, 2018
30/07/2018
SAN CARLOS, Calif., July 30, 2018 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology [...]
Immunomedics Announces Multiple Clinical and Preclinical Collaborations With Prominent Cancer Research Institutions
30/07/2018
Clinical Collaboration with Yale University to Evaluate Sacituzumab Govitecan in Two Phase 2 Studies in Endometrial and Cervical Cancers Research Collaborations with Yale University, Memorial Sloan Kettering Cancer [...]
Pernix Therapeutics Announces Successful Closing of Transaction Regarding Worldwide Rights to Contrave® for Weight Loss
30/07/2018
MORRISTOWN, N.J., July 30, 2018 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX), a specialty pharmaceutical company, today announced the closing of a transaction in which Nalpropion Pharmaceuticals [...]
Tauriga Sciences, Inc. Shares Now Listed on OTCQB Marketplace; Up-List Effective at Open of Trading Monday July 30, 2018
30/07/2018
NEW YORK, NY, July 30, 2018 (GLOBE NEWSWIRE) -- Tauriga Sciences, Inc. (OTCQB: TAUG) (OTCQB: TAUGD) (“Tauriga” or the “Company”), engaged in building its business through the development, distribution, and licensing of [...]
Soleno Therapeutics Receives Fast Track Designation from FDA for DCCR for Treatment of Prader-Willi Syndrome
30/07/2018
Phase III Clinical Trial Ongoing at Multiple Sites in the U.S. REDWOOD CITY, Calif., July 30, 2018 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ:SLNO), a clinical-stage biopharmaceutical company [...]
Apricus Biosciences, Inc. Announces Merger Agreement with Seelos Therapeutics, Inc. to Advance Late-Stage Pipeline of Products for Central Nervous System (CNS) Disorders
30/07/2018
Transaction to result in Nasdaq-listed company focused on developing novel products to treat central nervous system diseases Transaction expected to advance Seelos’ robust, late-stage pipeline of five programs, with [...]
BioDelivery Sciences Appoints Thomas Smith, MD as Chief Medical Officer Further Expanding Company’s Expertise in Field of Pain Management
30/07/2018
RALEIGH, N.C., July 30, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a leading commercial based specialty pharmaceutical company focused on patients living with chronic pain has [...]
Transactions under Novozymes’ stock buyback program
30/07/2018
Please read the full announcement in the attached PDF Attachment 2018_45_Stock_Buybackprogram_EN
Tyme Technologies Provides Clinical and Corporate Update for Fiscal 1Q 2019
30/07/2018
NEW YORK, July 30, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ:TYME), a clinical-stage oncology company developing metabolically-based cancer therapeutics, today announced a clinical and corporate update [...]
Novo Nordisk A/S - Share repurchase programme
30/07/2018
Bagsværd, Denmark, 30 July 2018 - On 4 May 2018, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR [...]
Sienna Biopharmaceuticals Announces Pivotal Trials with SNA-001 in Acne Did Not Meet Primary and Secondary Endpoints
30/07/2018
-- Results from independent pivotal trials with SNA-001 for the reduction of unwanted light-pigmented hair expected beginning in the fourth quarter of 2018 -- Sienna continues to advance robust multi-asset pipeline, [...]
Lexicon Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides a Business Update
30/07/2018
XERMELO ® (telotristat ethyl) Quarterly U.S. Net Sales of $6.0 Million, Up 65% from Prior Year Quarter and 11% Quarter-Over-Quarter Filings for Regulatory Approval of Sotagliflozin in Type 1 Diabetes Accepted THE [...]
CLS Exhibits Thermal Therapy Laser Ablation System at AdMeTech Annual Conference
30/07/2018
Unique Non-Cooled Fiber Technology Optimizes Heat Distribution, Eliminates External Cooling, Reduces Procedure Times FRAMINGHAM, Mass., July 30, 2018 (GLOBE NEWSWIRE) -- Clinical Laserthermia Systems Americas, Inc . ( [...]
Emerald Health Therapeutics’ Cannabis Joint Venture Pure Sunfarms Receives Sales License from Health Canada for 1.1 Million Square Foot Greenhouse
30/07/2018
Pure Sunfarms’ Delta 3 greenhouse facility becomes one of the largest Canadian cannabis growing operations licensed to sell product, with significant production and sales ramp expected through 2018 and beyond VANCOUVER [...]
RedHill Biopharma Announces Positive Top-Line Results from Phase III Study of RHB-104 in Crohn’s Disease
30/07/2018
Primary endpoint successfully achieved - superior remission rate at week 26 in patients treated with RHB-104 (p= 0.013) Key secondary endpoints also met, demonstrating consistent benefit to Crohn’s disease patients [...]

Pages